InvestorLens

RPRX — ROYALTY PHARMA PLC

Public company

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying RPRX?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Net accumulation · 1 buying vs 0 selling last quarter
68
Macro Tailwind
Macro conditions are mixed for this sector
56
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their RPRX position last quarter, 1 bought and 0 sold (100% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 56/100 in a Overheat regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (Ray Dalio)
  • +5 tracked investors reported holding RPRX at their latest filing
  • +Macro Health is 56/100 in a Overheat regime — historically acceptable for this sectorsource
Contradicting evidence — always shown
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 9/18/2026.

About ROYALTY PHARMA PLC (RPRX)

ROYALTY PHARMA PLC (RPRX) appears in the most recent 13F filings of 5 tracked institutional investors. The largest disclosed position is held by Andreas Halvorsen (Viking Global Investors), valued at $342M. Across recent filings, tracked investors recorded 5 new positions, 2 increased, 4 reduced, and 3 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in RPRX

50
/100
Mixed Activity
Added / Increased7
Reduced4
Exited3
BearishBullish
Crowded Trade Score™

How many top investors track RPRX

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

RPRX Ownership Composition

How ROYALTY PHARMA PLC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
67% of tracked value
Institutions
5
tracked investors
Total Reported
$142.8M
combined 13F value
Types2
  • Multi-Strategy / Quant67.4%
  • Macro32.6%
Multi-Strategy / Quant(3)
67.4%
Macro(2)
32.6%

Tracked investors currently reporting RPRX

1 tracked investor has since exited this position — listed separately below.

  • Ken GriffinJun 30, 2026
    Citadel Advisors
    Shares
    1.6M
    Value
    $89.2M
    % Portfolio
    0.01%
  • Izzy EnglanderJun 30, 2026
    Millennium Management
    Shares
    18.8K
    Value
    $1.1M
    % Portfolio
    0.00%
  • Paul Tudor JonesJun 30, 2026
    Tudor Investment Corp
    Shares
    610.7K
    Value
    $34.2M
    % Portfolio
    0.05%
  • Steve CohenJun 30, 2026
    Point72 Asset Management
    Shares
    106.5K
    Value
    $6M
    % Portfolio
    0.01%
  • Ray DalioJun 30, 2026
    Bridgewater Associates
    Shares
    219.7K
    Value
    $12.3M
    % Portfolio
    0.05%

Previously held RPRX

These investors reported RPRX in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Andreas HalvorsenViking Global Investors2.6M$93.6MJun 30, 2025

Recent activity

Frequently asked questions

How many institutional investors hold RPRX?
5 tracked institutional investors disclosed a position in RPRX (ROYALTY PHARMA PLC) in their most recent 13F filing.
Who is the largest institutional holder of RPRX?
Andreas Halvorsen, Viking Global Investors, holds the largest disclosed position in RPRX, valued at $342M.
Did institutional ownership of RPRX increase or decrease?
Across recent 13F filings, tracked investors recorded 5 new positions, 2 increased, 4 reduced, and 3 fully exited RPRX.
Where does this RPRX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.